Literature DB >> 12939440

Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency.

Mette C Ørngreen1, Rasmus Ejstrup, John Vissing.   

Abstract

It is generally believed that a diet high in carbohydrate improves exercise tolerance in patients with carnitine palmitoyltransferase II (CPT II) deficiency, but it has never been systematically investigated. The authors investigated the effect of a high- vs low-carbohydrate diet on exercise tolerance in four patients with CPT II, who cycled at a constant workload of 50% of VO2max. Exercise tolerance, assessed by exercise duration and perceived exertion, improved on the carbohydrate-rich diet.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939440     DOI: 10.1212/01.wnl.0000078195.05396.20

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

Authors:  Mette Cathrine Ørngreen; Karen Lindhardt Madsen; Nicolai Preisler; Grete Andersen; John Vissing; Pascal Laforêt
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

3.  No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.

Authors:  Mette Cathrine Ørngreen; John Vissing; Pascal Laforét
Journal:  J Inherit Metab Dis       Date:  2014-10-21       Impact factor: 4.982

Review 4.  The functions of cardiolipin in cellular metabolism-potential modifiers of the Barth syndrome phenotype.

Authors:  Vaishnavi Raja; Miriam L Greenberg
Journal:  Chem Phys Lipids       Date:  2014-01-17       Impact factor: 3.329

Review 5.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 6.  Disorders of carnitine transport and the carnitine cycle.

Authors:  Nicola Longo; Cristina Amat di San Filippo; Marzia Pasquali
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

Review 7.  Therapeutic options in other metabolic myopathies.

Authors:  Matthias Vorgerd
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.

Authors:  C R Roe; B-Z Yang; H Brunengraber; D S Roe; M Wallace; B K Garritson
Journal:  Neurology       Date:  2008-07-22       Impact factor: 9.910

9.  New insight into the role of MMP14 in metabolic balance.

Authors:  Hidetoshi Mori; Ramray Bhat; Alexandre Bruni-Cardoso; Emily I Chen; Danielle M Jorgens; Kester Coutinho; Katherine Louie; Benjamin Ben Bowen; Jamie L Inman; Victoria Tecca; Sarah J Lee; Sabine Becker-Weimann; Trent Northen; Motoharu Seiki; Alexander D Borowsky; Manfred Auer; Mina J Bissell
Journal:  PeerJ       Date:  2016-07-13       Impact factor: 2.984

Review 10.  Perspectives on Exertional Rhabdomyolysis.

Authors:  Eric S Rawson; Priscilla M Clarkson; Mark A Tarnopolsky
Journal:  Sports Med       Date:  2017-03       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.